Catalog # HP9006
IL-8, Human, pAb
Please choose the quantity of items you wish to add to your cart…
Find distributor The polyclonal antibody reacts with human natural and recombinant Interleukin-8 (IL-8) as assessed by ELISA. The antibody inhibits the biological activity of human native and recombinant IL-8. The antibody cross reacts with rhesus and cynomolgus natural IL-8.
Application
Functional studies, Immuno assays, Immuno precipitation, Western blot
Use
Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.
Product type
Polyclonal antibodies
Amount
100 µg, 20 µg
Formulation
0.2 ml (100 μg/ml) of 0.2 μm filtered protein A purified antibody solution in PBS and 0.1% bovine serum albumin. The endotoxin concentration is < 24 EU/mg, determined with HIT302 LAL Assay.
Isotype
Rabbit Ig
Species
Human
Cross reactivity
Cynomolgus monkey – Yes, Monkey – Yes, Rhesus monkey – Yes
Alias
Interleukin-8, C-X-C motif chemokine 8, Emoctakin, Granulocyte chemotactic protein 1, T-cell chemotactic factor</br> -
Gene name: CXCL8
Storage and stability
Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.
Precautions
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result with the use of or derivation of this product.
Disease
Autoimmunity, Tumor immunology
Protocol
CoA-TDS pAb
Safety Data Sheet
Powered by BiozLatest Hycult Biotech news
- Discover Cross-Reactive Complement ELISA for NHP Research
Bridging Human and NHP Complement Research. At Hycult Biotech, we understand the importance of testing therapeutic agents on non-human primates (NHP) samples in order to get approval to enter clinical phases. That is why we have committed to the following initiative: Testing our existing complement ELISA assays for NHP research. Why Non Human Primate Samples… Read more: Discover Cross-Reactive Complement ELISA for NHP Research - New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
